Apogee Therapeutics has a strong financial health with a cash reserve of $913 million, supporting operations until 2028.Citigroup maintains a "Buy" rating for Apogee Therapeutics, highlighting confidence in the company's future.Apogee's drug, Zumilokibart, shows promise with an extended half-life and a clean safety profile, potentially enhancing its market position.Apogee Therapeutics (NASDAQ:APGE) is a company focused on advancing treatments in the field of immunology. It is working on optimizing the IL-13 ...